Our products and technologies are designed to harness the power of the immune system to improve the treatment of cancer. We are developing active immunotherapies that target not only regular tumor cells, but also the cancer stem cells believed to cause cancer growth and recurrence. Using our proprietary discovery technology, we also identify and develop monoclonal antibodies that may be used to treat a wide range of cancers. Our most advanced clinical programs are in glioblastoma multiforme (GBM). Our product candidates also have potential applications in other cancers with high unmet medical need.